U
BRLI

UBS’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

UBS’s Portfolio BRLI Stock Details BRLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$722K Buy
25,748
+1,295
+5% +$39.4K ﹤0.01% 3911
2014
Q2 		$739K Sell
24,453
-213
-0.9% -$5.88K ﹤0.01% 3843
2014
Q1 		$683K Sell
24,666
-5,168
-17% -$135K ﹤0.01% 3915
2013
Q4 		$762K Buy
29,834
+12,346
+71% +$380K ﹤0.01% 3843
2013
Q3 		$523K Sell
17,488
-17,640
-50% -$491K ﹤0.01% 4088
2013
Q2 		$1.01M Buy
+35,128
New +$968K ﹤0.01% 3327

Other funds holding BRLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's BRLI Position: Q3 2014 in Review

UBS increased its BIO-REFERENCE LABS INC-NEW- (BRLI) stake by 5.3% in Q3 2014, buying an estimated $39.4K and bringing the position to 25,748 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

UBS first reported a position in BRLI in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.01M in Q2 2013. 168 funds tracked by Wall St. Rank hold BRLI as of Q3 2014.

  • UBS held 25,748 shares of BIO-REFERENCE LABS INC-NEW- worth $722K as of Q3 2014.
  • UBS bought 1,295 BIO-REFERENCE LABS INC-NEW- shares in Q3 2014, an estimated $39.4K.
  • BIO-REFERENCE LABS INC-NEW- made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3911 holding.
  • UBS first reported a position in BIO-REFERENCE LABS INC-NEW- in Q2 2013 and has held it in 6 quarters since.
  • UBS's BIO-REFERENCE LABS INC-NEW- position peaked at $1.01M in Q2 2013.
  • 168 funds tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.